All News
Can HCQ prevent SLE? Results of the MONA-LISA study is being analyzed (pts have +ANA and 1-2 SLICC criteria for SLE randomized to PCB or HCQ) - @DrDavidKarp @rheumnow #RNL2024 https://t.co/9yoFXS7wMe
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@DrDavidKarp
Incomplete lupus is heterogeneous term
"Stage 2" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/CuLUzSZ24E
Links:
Eric Dein ericdeinmd ( View Tweet)
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Appreciative inquiry in rheumatology and how to enhance and improve our clinical notes to frame our encounter in a positive manner.
@BharatKumarMD
#RNL2024
@RheumNow https://t.co/iTXwjUb6tg
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober.
Great talk.
#RNL2024
@RheumNow https://t.co/fuRsSnnsha
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Alopecia aerate and JAK
Bruce Strober
#RNL2024
@RheumNow https://t.co/lGig1Vpf5x
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK safety and malignancy risk.
Great talk by kevin Winthrop.
#RNL2024
@RheumNow https://t.co/d7WRHJxrpM
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@BharatKumarMD at #RNL2024 @RheumNow
Appreciative Inquiry in Rheumatology
5(ish) steps
Dawn (what focus on) -> Discovery (what gives life) -> Dream (what might be) -> Design (what should be) -> Destiny (how can i execute) -> New Dawn
- Empathy at center of inquiry https://t.co/gDhXpi94pT
Eric Dein ericdeinmd ( View Tweet)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Disease activity indices may perform differently in man and women.
@lihi_eder
#RNL2024
@RheumNow https://t.co/8G1D0pGKe8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
I am jealous of the derms who have topical JAKi!
Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex KDAO2011 ( View Tweet)
JAK and TYK2 signaling pathways.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/WxoZGCEL0z
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAKinib negatives.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/vVzSQMVa5a
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
"Any vacuolar interface dermatitis will respond to a JAKi" - Dr. B Strober noted JAKi will work for cutaneous lupus #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Have you seen tachyphylaxis in JAKi? #RNL2024 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)